Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ACR | P10323 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794013 | 0.89 | POLB (0.61) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL788710 | 0.82 | KMT2A (0.69) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL787810 | 0.81 | LMNA (0.58) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL793716 | 0.78 | LMNA (0.61) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL787881 | 0.77 | LMNA (0.78) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL23494163 | 0.77 | POLB (1.00) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL31307818 | 0.77 | POLB (1.00) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL27424282 | 0.72 | POLB (0.59) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL795340 | 0.71 | PFKFB3 (0.58) | POLBLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL787595 | 0.71 | MAPT (0.51) | POLBLMNATP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | claimed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | claimed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | POLB 1101/4885LMNA 4383/4885TP53 2372/4885 |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | POLB 2562/4885LMNA 1654/4885TP53 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.